Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: CYP3A Phenotyping|CYP3A5 and MDR1 Genotyping|Docetaxel Toxicity|Associations Between Genetic Data and Docetaxel Toxicity
Interventions: DRUG: docetaxel + CEF
Sponsor: University of Turku
Collaborators: Sanofi|Turku University Hospital|Vaasa Central Hospital, Vaasa, Finland|medbase Oy Ltd